Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are
characterized by uncontrolled activation of intestinal immune cells in a genetically …

Vedolizumab is a novel therapeutic monoclonal antibody recently approved for the treatment
of moderately to severely active ulcerative colitis and Crohn's disease in adults who have …

Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammation of the
gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and …

Intestinal immune cell trafficking has been identified as a central event in the pathogenesis
of inflammatory bowel diseases (IBD). Intensive research on different aspects of the immune …

Background & Aims Vedolizumab is effective and safe for the treatment of Crohn's disease
(CD) and ulcerative colitis (UC). Little is known about the incidence rate of loss of response …

Vedolizumab is a humanized anti-α 4 β 7 integrin monoclonal antibody that selectively
blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α 4 β 7-mucosal …

Objective Gut homing of lymphocytes via adhesion molecules has recently emerged as new
target for therapy in IBDs. We aimed to analyse the in vivo homing of effector (Teff) and …

Objective The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for
the treatment of IBDs. This leads to a wide range of serum concentrations in patients and …

As one of the ligands of aryl hydrocarbon receptor (AhR), baicalein, isolated from Scutellaria
baicalensis Georgi, has been proved to exert potential therapeutic effects on ulcerative …

Background & Aims Oral therapies targeting the integrin α4β7 may offer unique advantages
for the treatment of inflammatory bowel disease. We characterized the oral α4β7 antagonist …